Antifibrotic therapy in patients with acute lung injury: a systematic review and meta-analysis

Background: Pulmonary fibrosis is a progressive and often irreversible condition that can develop following acute lung injury (ALI), particularly in patients requiring prolonged mechanical ventilation. Antifibrotic agents such as pirfenidone and nintedanib slow fibrosis progression in idiopathic pulmonary fibrosis, but their role in post-ALI fibrosis remains unclear. This meta-analysis aimed to evaluate the effects of antifibrotic therapy on mortality and secondary outcomes in patients with ALI. Methods: We searched Embase, PubMed, and Cochrane up to 17 March 2025 for randomized controlled trials and observational studies comparing antifibrotic therapy to standard care in patients with ALI. The primary outcome was all-cause mortality at the longest follow-up available. Secondary outcomes were length of hospital stay and radiological and functional findings. Results: We identified six studies (two randomized, two propensity matched and two case control studies) for a total of 697 COVID-19 patients and no study performed on non-COVID-19 patients. Antifibrotic therapy was associated with a significant reduction in all-cause mortality compared to the control group (16.1% vs. 23.9%, OR 0.61, 95% CI 0.40–0.93, p = 0.02, I2 = 40%). The number needed to treat to prevent one death was 13. There was no significant difference in length of hospital stay between the antifibrotic and control groups. Individual studies reported improvements in computed tomography severity scores and pulmonary function parameters in the antifibrotic group. Conclusions: This meta-analysis suggests that antifibrotic therapy might reduce mortality in patients with ALI. Improvements in radiological and functional outcomes indicate a potential role for antifibrotic agents in modifying disease progression. Further well-designed randomized controlled trials are necessary to confirm these results and determine the optimal use of antifibrotic therapy in post-ALI fibrosis. The PROSPERO Registration: The study protocol was prospectively registered in PROSPERO (registration number CRD420251001885).

Antifibrotics; Pirfenidone; Nintedanib; Acute respiratory distress syndrome; Acute lung injury; Intensive care unit

[1] Deng Z, Fear MW, Suk Choi Y, Wood FM, Allahham A, Mutsaers SE, et al. The extracellular matrix and mechanotransduction in pulmonary fibrosis. The International Journal of Biochemistry & Cell Biology. 2020; 126: 105802.

[2] Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. International Journal of Molecular Sciences. 2023; 24: 7849.

[3] Babariya H, Gaidhane SA, Acharya S, Kumar S. Pirfenidone as a cornerstone in the management of fibrotic interstitial lung diseases and its emerging applications: a comprehensive review. Cureus. 2024; 16: e70497.

[4] Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evidence. 2015; 10: 89–98.

[5] Wang J, Li K, Hao D, Li X, Zhu Y, Yu H, et al. Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm. 2024; 5: e744.

[6] Sturgill JL, Mayer KP, Kalema AG, Dave K, Mora S, Kalantar A, et al. Post-intensive care syndrome and pulmonary fibrosis in patients surviving ARDS-pneumonia of COVID-19 and non-COVID-19 etiologies. Scientific Reports. 2023; 13: 6554.

[7] Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. European Respiratory Journal. 2014; 43: 276–285.

[8] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. 2021; 372: n71.

[9] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine. 2009; 151: 264–269, W64.

[10] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology. 2014; 14: 135.

[11] Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JP. Critical interpretation of Cochran’s Q test depends on power and prior assumptions about heterogeneity. Research Synthesis Methods. 2010; 1: 149–161.

[12] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. The BMJ. 2003; 327: 557–560.

[13] Higgins JP, Douglas GA. Assessing risk of bias in included studies. In Higgins JP, Green S (eds.) Cochrane handbook for systematic reviews of interventions (pp. 187–243). 2nd edn. Wiley Blackwell: Hoboken. 2019.

[14] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. The BMJ. 2019; 366: l4898.

[15] Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. The BMJ. 2016; 355: i4919.

[16] Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations. The BMJ. 2004; 328: 1490.

[17] Boshra MS, Abou Warda AE, Sayed MA, Elkomy MH, Alotaibi NH, Mohsen M, et al. Effect of pirfenidone on risk of pulmonary fibrosis in COVID-19 patients experiencing cytokine storm. Healthcare. 2022; 10: 2387.

[18] Zhang F, Wei Y, He L, Zhang H, Hu Q, Yue H, et al. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chinese Medical Journal. 2021; 135: 368–370.

[19] Saiphoklang N, Patanayindee P, Ruchiwit P. The effect of nintedanib in post-COVID-19 lung fibrosis: an observational study. Critical Care Research and Practice. 2022; 2022: 9972846.

[20] Wang HY, Tsai SC, Lin YC, Hou JU, Chao CH. The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks. BMC Pulmonary Medicine. 2024; 24: 160.

[21] Acat M, Yildiz Gulhan P, Oner S, Turan MK. Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. International Journal of Clinical Practice. 2021; 75: e14961.

[22] Singh P, Behera D, Gupta S, Deep A, Priyadarshini S, Padhan P. Nintedanib vs. pirfenidone in the management of COVID-19 lung fibrosis: a single-centre study. Journal of the Royal College of Physicians of Edinburgh. 2022; 52: 100–104.

[23] Kou M, Jiao Y, Li Z, Wei B, Li Y, Cai Y, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2024; 80: 1445–1460.

[24] Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Molecular Medicine. 2020; 26: 49.

[25] Ying H, Fang M, Hang QQ, Chen Y, Qian X, Chen M. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway. Journal of Cellular and Molecular Medicine. 2021; 25: 8662–8675.

[26] Da X, Li Z, Huang X, He Z, Yu Y, Tian T, et al. AGGF1 therapy inhibits thoracic aortic aneurysms by enhancing integrin α7-mediated inhibition of TGF-β1 maturation and ERK1/2 signaling. Nature Communications. 2023; 14: 2265.

[27] Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. Rheumatology International. 2020; 40: 703–710.

[28] Wei Q, Kong N, Liu X, Tian R, Jiao M, Li Y, et al. Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro. Journal of Translational Medicine. 2021; 19: 157.

[29] Seifirad S. Pirfenidone: a novel hypothetical treatment for COVID-19. Medical Hypotheses. 2020; 144: 110005.

[30] Liang Y, Yan Y, Liu N, Wang J, Fang C. Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis. Journal of Ethnopharmacology. 2024; 329: 118153.

[31] Shi SY, Zhao LW, Liu CB, Xiao HM, Jiang ZJ. Pirfenidone promotes cell cycle arrest and apoptosis of triple-negative breast cancer cells by suppressing Hedgehog/GLI1 signaling. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025; 398: 5915–5925.

[32] Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Shintani A, Hashimoto S, et al. Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia. Scientific Reports. 2021; 11: 20051.

[33] Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Translational Research. 2022; 241: 13–24.

[34] Torre A, Martínez-Sánchez FD, Narvaez-Chávez SM, Herrera-Islas MA, Aguilar-Salinas CA, Córdova-Gallardo J. Pirfenidone use in fibrotic diseases: what do we know so far? Immunity, Inflammation and Disease. 2024; 12: e1335.

[35] Liu G, Dong BB, Devanarayana S, Chen RC, Liu Q. Emerging roles of mechanosensitive ion channels in ventilator induced lung injury: a systematic review. Frontiers in Immunology. 2024; 15: 1479230.

[36] Zangrillo A, Belletti A, Palumbo D, Calvi MR, Guzzo F, Fominskiy EV, et al. One-year multidisciplinary follow-up of patients with COVID-19 requiring invasive mechanical ventilation. Journal of Cardiothoracic and Vascular Anesthesia. 2022; 36: 1354–1363.

[37] Tresoldi M, Zangrillo A, Belletti A, Ramirez GA, Bozzolo E, Guzzo F, et al. Two-year multidisciplinary follow-up of COVID-19 patients requiring invasive and noninvasive respiratory support. Minerva Medica. 2023; 114: 773–784.

[38] D’Amico F, Marmiere M, Fonti M, Battaglia M, Belletti A. Association does not mean causation, when observational data were misinterpreted as causal: the observational interpretation fallacy. Journal of Evaluation in Clinical Practice. 2025; 31: e14288.

[39] Monti G, Marzaroli M, Tucciariello MT, Ferrara B, Meroi F, Nakhnoukh C, et al. Pirfenidone to prevent fibrosis in acute respiratory distress syndrome: the PIONEER study protocol. Contemporary Clinical Trials. 2025; 153: 107883.

[40] D’Amico F, Marmiere M, Monti G, Landoni G. Protective hemodynamics: C.L.E.A.R.! Journal of Cardiothoracic and Vascular Anesthesia. 2025; 39: 13–19.

[41] D’Amico F, Landoni G. Protective hemodynamics: a novel strategy to manage blood pressure. Current Opinion in Critical Care. 2024; 30: 629–636.